Immutep Limited (IMMP)
IMMP Stock Price Chart
Explore Immutep Limited interactive price chart. Choose custom timeframes to analyze IMMP price movements and trends.
IMMP Company Profile
Discover essential business fundamentals and corporate details for Immutep Limited (IMMP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Apr 2012
Employees
53.00
Website
https://www.immutep.comCEO
Marc Voigt
Description
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
IMMP Financial Timeline
Browse a chronological timeline of Immutep Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Sept 2026
EPS estimate is -$0.05, while revenue estimate is $3.70m.
Earnings released on 24 Feb 2026
EPS came in at -$0.22 falling short of the estimated -$0.20 by -9.90%, while revenue for the quarter reached $5.50m , missing expectations by -41.49%.
Earnings released on 28 Aug 2025
EPS came in at -$0.18 falling short of the estimated -$0.12 by -44.02%, while revenue for the quarter reached $1.24m .
Earnings released on 26 Feb 2025
EPS came in at -$0.01 surpassing the estimated -$0.08 by +88.73%, while revenue for the quarter reached $1.95m , beating expectations by +349.69%.
Earnings released on 30 Aug 2024
EPS came in at -$0.01 surpassing the estimated -$0.08 by +86.12%, while revenue for the quarter reached $1.15m , missing expectations by -6.60%.
Earnings released on 29 Apr 2024
EPS came in at -$0.01 surpassing the estimated -$0.09 by +86.06%, while revenue for the quarter reached $1.44m , beating expectations by +19.64%.
Earnings released on 28 Sept 2023
EPS came in at -$0.01 surpassing the estimated -$0.09 by +84.81%, while revenue for the quarter reached $1.21m , missing expectations by -14.40%.
Earnings released on 24 Feb 2023
EPS came in at -$0.02 surpassing the estimated -$0.08 by +80.82%, while revenue for the quarter reached $1.15m .
Earnings released on 28 Jul 2022
EPS came in at -$0.01 , while revenue for the quarter reached $702.84k , beating expectations by +4.25%.
Earnings released on 22 Feb 2022
EPS came in at -$0.01 surpassing the estimated -$0.23 by +94.03%, while revenue for the quarter reached $1.51m , missing expectations by -4.19%.
Earnings released on 30 Aug 2021
EPS came in at -$0.01 surpassing the estimated -$0.38 by +97.41%, while revenue for the quarter reached $1.24m , missing expectations by -13.79%.
IMMP Stock Performance
Access detailed IMMP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
